Cochrane · systematic review · CD007888
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
Fisher, SA, Doree, C, Mathur, A, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 14.3%Very low 0 · 0%Low 6 · 85.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsBone marrow‐derived cell therapy for people with chronic ischaemic heart disease and congestive heart failure
Population: people with chronic ischaemic heart disease and congestive heart failure
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all cause) Long‐term | RR 0.42 [0.21, 0.87] | 9 studies · 491 participants | Low Downgraded: risk of bias, imprecision |
Periprocedural adverse events | no estimate extracted | 34 studies · 1695 participants | Ungraded |
Non‐fatal myocardial infarction Long‐term | RR 0.38 [0.15, 0.97] | 5 studies · 345 participants | Low Downgraded: risk of bias, imprecision |
Rehospitalisation due to heart failure Long‐term | RR 0.63 [0.36, 1.09] | 6 studies · 375 participants | Low Downgraded: risk of bias, imprecision |
Arrhythmias Long‐term | RR 0.42 [0.18, 0.99] | 1 study · 82 participants | Low Downgraded: risk of bias, imprecision |
Composite MACE Long‐term | RR 0.64 [0.38, 1.08] | 3 studies · 141 participants | Low Downgraded: risk of bias, imprecision |
LVEF (%) measured by MRI Long‐term | no estimate extracted | 1 study · 25 participants | Low Downgraded: risk of bias, imprecision |